These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36698428)

  • 1. Medical uses for phenol in the urinary tract: A possible forgotten treatment (Review).
    Sadahira T; Maruyama Y; Watanabe T; Sekito T; Mitsui Y; Wada K; Araki M; Watanabe M
    Med Int (Lond); 2021; 1(4):13. PubMed ID: 36698428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Therapeutic Strategies in Clinical Urology.
    Crane A; Isharwal S; Zhu H
    Mol Pharm; 2018 Aug; 15(8):3010-3019. PubMed ID: 29924627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.
    Chung E
    Expert Opin Biol Ther; 2015 Jan; 15(1):95-102. PubMed ID: 25347039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia.
    Hu H; Zhang W; Liu X; Wang H; Fang Z; Liang C; Wang T; Xu K
    J Urol; 2018 Sep; 200(3):620-625. PubMed ID: 29630981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(17):1-121. PubMed ID: 23074487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Botulinum Toxin in Urologic Diseases.
    Chermansky CJ; Chancellor MB
    Urology; 2016 May; 91():21-32. PubMed ID: 26777748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The unusual history and the urological applications of botulinum neurotoxin.
    Hanchanale VS; Rao AR; Martin FL; Matanhelia SS
    Urol Int; 2010; 85(2):125-30. PubMed ID: 20664247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urobiome: An outlook on the metagenome of urological diseases.
    Shoemaker R; Kim J
    Investig Clin Urol; 2021 Nov; 62(6):611-622. PubMed ID: 34729961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.
    Lewis AL; Young GJ; Selman LE; Rice C; Clement C; Ochieng CA; Abrams P; Blair PS; Chapple C; Glazener CM; Horwood J; McGrath JS; Noble S; Taylor GT; Lane JA; Drake MJ
    Health Technol Assess; 2020 Sep; 24(42):1-122. PubMed ID: 32902375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review).
    Dan Spinu A; Gabriel Bratu O; Cristina Diaconu C; Maria Alexandra Stanescu A; Bungau S; Fratila O; Bohiltea R; Liviu Dorel Mischianu D
    Exp Ther Med; 2020 Jul; 20(1):117-120. PubMed ID: 32509003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
    Hsu YC; Wang HJ; Chuang YC
    Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portable bladder ultrasound: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(11):1-51. PubMed ID: 23074481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
    Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
    Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.
    Jindan L; Xiao W; Liping X
    Drug Des Devel Ther; 2022; 16():2861-2884. PubMed ID: 36051157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery for the treatment of overactive bladder.
    Appell RA
    Urology; 1998 Feb; 51(2A Suppl):27-9. PubMed ID: 9495732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review.
    Bogart LM; Berry SH; Clemens JQ
    J Urol; 2007 Feb; 177(2):450-6. PubMed ID: 17222607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT.
    Worthington J; Lane JA; Taylor H; Young G; Noble SM; Abrams P; Ahern A; Brookes ST; Cotterill N; Johnson L; Khan R; Fernandez AM; Page T; Swami S; Hashim H
    Health Technol Assess; 2020 Sep; 24(41):1-96. PubMed ID: 32901611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cystectomy for non-malignant bladder conditions: a review.
    Chong JT; Dolat MT; Klausner AP; Dragoescu E; Hampton LJ
    Can J Urol; 2014 Oct; 21(5):7433-41. PubMed ID: 25347367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.